Leniolisib (CDZ173)

Biorbyt

Leniolisib (CDZ173) [1354690-24-6]

16

1354690-24-6

Research Use Only

C21H25F3N6O2

450.4574

Leniolisib (CDZ173) is a potent and selective PI3Kdelta inhibitor currently in phase II/III clinical trials for the treatment of immunodeficiency disorders.

FC(C1=C(N=C([H])C(=C1[H])N1C([H])([H])C([H])([H])C2=C(C1([H])[H])C(=NC([H])=N2)N([H])[C@]1([H])C([H])([H])N(C(C([H])([H])C([H])([H])[H])=O)C([H])([H])C1([H])[H])OC([H])([H])[H])(F)F

12352200